{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:22:59Z","timestamp":1786980179321,"version":"build-2736575974"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T00:00:00Z","timestamp":1692748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T00:00:00Z","timestamp":1692748800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100003243","name":"Ministerstvo Zdravotnictv\u00ed Cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["NV19-03-00007"],"award-info":[{"award-number":["NV19-03-00007"]}],"id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virchows Arch"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1007\/s00428-023-03629-z","type":"journal-article","created":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T11:01:51Z","timestamp":1692788511000},"page":"509-516","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Immunohistochemical expression of PRAME in 485 cases of epithelial tubo-ovarian tumors"],"prefix":"10.1007","volume":"483","author":[{"given":"Adam","family":"\u0160afanda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"Kendall B\u00e1rt\u016f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romana","family":"Mich\u00e1lkov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Stru\u017einsk\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Drozenov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavel","family":"Fabi\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jitka","family":"Hausnerov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Laco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radoslav","family":"Mat\u011bj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petr","family":"\u0160kapa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari\u00e1n","family":"\u0160vajdler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuzana","family":"\u0160p\u016frkov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e1bor","family":"M\u00e9hes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavel","family":"Dundr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9340-9320","authenticated-orcid":false,"given":"Krist\u00fdna","family":"N\u011bmejcov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,23]]},"reference":[{"key":"3629_CR1","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1034\/j.1600-065x.2002.18803.x","volume":"188","author":"MJ Scanlan","year":"2002","unstructured":"Scanlan MJ, Gure AO, Jungbluth AA, Old LJ, Chen YT (2002) Cancer\/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev 188:22\u201332. https:\/\/doi.org\/10.1034\/j.1600-065x.2002.18803.x","journal-title":"Immunol Rev"},{"issue":"2","key":"3629_CR2","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/s1074-7613(00)80426-4","volume":"6","author":"H Ikeda","year":"1997","unstructured":"Ikeda H, Leth\u00e9 B, Lehmann F, van Baren N, Baurain JF, de Smet C, Chambost H, Vitale M, Moretta A, Boon T, Coulie PG (1997) Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity 6(2):199\u2013208. https:\/\/doi.org\/10.1016\/s1074-7613(00)80426-4","journal-title":"Immunity"},{"key":"3629_CR3","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1111\/j.1349-7006.2009.01303.x","volume":"100","author":"OL Caballero","year":"2009","unstructured":"Caballero OL, Chen Y-T (2009) Cancer\/testis (CT) antigens: Potential targets for immunotherapy. Cancer Sci 100:2014\u20132021. https:\/\/doi.org\/10.1111\/j.1349-7006.2009.01303.x","journal-title":"Cancer Sci"},{"issue":"4","key":"3629_CR4","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1158\/2326-6066.CIR-13-0088","volume":"2","author":"J Yao","year":"2014","unstructured":"Yao J, Caballero OL, Yung WK, Weinstein JN, Riggins GJ, Strausberg RL, Zhao Q (2014) Tumor subtype-specific cancer-testis antigens as potential biomarkers and immunotherapeutic targets for cancers. Cancer Immunol Res 2(4):371\u2013379. https:\/\/doi.org\/10.1158\/2326-6066.CIR-13-0088","journal-title":"Cancer Immunol Res"},{"key":"3629_CR5","doi-asserted-by":"publisher","first-page":"8828579","DOI":"10.1155\/2020\/8828579","volume":"2020","author":"J Li","year":"2020","unstructured":"Li J, Yin J, Zhong J, Yang Z, Tang A, Li S (2020) Clinicopathological and Prognostic Significance of PRAME Overexpression in Human Cancer: A Meta-Analysis. Biomed Res Int 2020:8828579. https:\/\/doi.org\/10.1155\/2020\/8828579","journal-title":"Biomed Res Int"},{"issue":"17","key":"3629_CR6","doi-asserted-by":"publisher","first-page":"6092","DOI":"10.1073\/pnas.0501564102","volume":"102","author":"C Haqq","year":"2005","unstructured":"Haqq C, Nosrati M, Sudilovsky D, Crothers J, Khodabakhsh D, Pulliam BL, Federman S, Miller JR 3rd, Allen RE, Singer MI, Leong SP, Ljung BM, Sagebiel RW, Kashani-Sabet M (2005) The gene expression signatures of melanoma progression. Proc Natl Acad Sci U S A 102(17):6092\u20136097. https:\/\/doi.org\/10.1073\/pnas.0501564102","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"22","key":"3629_CR7","doi-asserted-by":"publisher","first-page":"10639","DOI":"10.1158\/0008-5472.CAN-06-2522","volume":"66","author":"T Mirjam","year":"2006","unstructured":"Mirjam T (2006) Epping, Ren\u00e9 Bernards; A Causal Role for the Human Tumor Antigen Preferentially Expressed Antigen of Melanoma in Cancer. Cancer Res 66(22):10639\u201310642. https:\/\/doi.org\/10.1158\/0008-5472.CAN-06-2522","journal-title":"Cancer Res"},{"issue":"18","key":"3629_CR8","first-page":"4090","volume":"58","author":"E Neumann","year":"1998","unstructured":"Neumann E, Engelsberg A, Decker J, St\u00f6rkel S, Jaeger E, Huber C, Seliger B (1998) Heterogeneous expression of the tumor-associated antigens RAGE-1, PRAME, and glycoprotein 75 in human renal cell carcinoma: candidates for T-cell-based immunotherapies? Cancer Res 58(18):4090\u20134095","journal-title":"Cancer Res"},{"issue":"2","key":"3629_CR9","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.lungcan.2009.04.010","volume":"67","author":"J Bankovic","year":"2010","unstructured":"Bankovic J, Stojsic J, Jovanovic D, Andjelkovic T, Milinkovic V, Ruzdijic S, Tanic N (2010) Identification of genes associated with non-small-cell lung cancer promotion and progression. Lung Cancer 67(2):151\u2013159. https:\/\/doi.org\/10.1016\/j.lungcan.2009.04.010","journal-title":"Lung Cancer"},{"issue":"13","key":"3629_CR10","doi-asserted-by":"publisher","first-page":"4307","DOI":"10.1158\/1078-0432.CCR-03-0813","volume":"10","author":"A Oberthuer","year":"2004","unstructured":"Oberthuer A, Hero B, Spitz R, Berthold F, Fischer M (2004) The tumor-associated antigen PRAME is universally expressed in high-stage neuroblastoma and associated with poor outcome. Clin Cancer Res 10(13):4307\u20134313. https:\/\/doi.org\/10.1158\/1078-0432.CCR-03-0813","journal-title":"Clin Cancer Res"},{"issue":"2","key":"3629_CR11","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s10549-007-9643-3","volume":"109","author":"P Doolan","year":"2008","unstructured":"Doolan P, Clynes M, Kennedy S, Mehta JP, Crown J, O\u2019Driscoll L (2008) Prevalence and prognostic and predictive relevance of PRAME in breast cancer. Breast Cancer Res Treat 109(2):359\u2013365. https:\/\/doi.org\/10.1007\/s10549-007-9643-3","journal-title":"Breast Cancer Res Treat"},{"key":"3629_CR12","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s13569-017-0077-3","volume":"7","author":"J Roszik","year":"2017","unstructured":"Roszik J, Wang WL, Livingston JA, Roland CL, Ravi V, Yee C, Hwu P, Futreal A, Lazar AJ, Patel SR, Conley AP (2017) Overexpressed PRAME is a potential immunotherapy target in sarcoma subtypes. Clin Sarcoma Res 7:11. https:\/\/doi.org\/10.1186\/s13569-017-0077-3","journal-title":"Clin Sarcoma Res"},{"issue":"6","key":"3629_CR13","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1001\/jamaophthalmol.2017.0729","volume":"135","author":"G Gezgin","year":"2017","unstructured":"Gezgin G, Luk SJ, Cao J, Dogrus\u00f6z M, van der Steen DM, Hagedoorn RS, Krijgsman D, van der Velden PA, Field MG, Luyten GPM, Szuhai K, Harbour JW, Jordanova ES, Heemskerk MHM, Jager MJ (2017) PRAME as a Potential Target for Immunotherapy in Metastatic Uveal Melanoma. JAMA Ophthalmol 135(6):541\u2013549. https:\/\/doi.org\/10.1001\/jamaophthalmol.2017.0729","journal-title":"JAMA Ophthalmol"},{"issue":"12","key":"3629_CR14","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.3324\/haematol.13214","volume":"93","author":"C Santamar\u00eda","year":"2008","unstructured":"Santamar\u00eda C, Chill\u00f3n MC, Garc\u00eda-Sanz R, Balanzategui A, Sarasquete ME, Alcoceba M, Ramos F, Bernal T, Queiz\u00e1n JA, Pe\u00f1arrubia MJ, Giraldo P, San Miguel JF, Gonzalez M (2008) The relevance of preferentially expressed antigen of melanoma (PRAME) as a marker of disease activity and prognosis in acute promyelocytic leukemia. Haematologica 93(12):1797\u20131805. https:\/\/doi.org\/10.3324\/haematol.13214","journal-title":"Haematologica"},{"issue":"2","key":"3629_CR15","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/s0165-4608(01)00570-2","volume":"133","author":"D Steinbach","year":"2002","unstructured":"Steinbach D, Hermann J, Viehmann S, Zintl F, Gruhn B (2002) Clinical implications of PRAME gene expression in childhood acute myeloid leukemia. Cancer Genet Cytogenet 133(2):118\u2013123. https:\/\/doi.org\/10.1016\/s0165-4608(01)00570-2","journal-title":"Cancer Genet Cytogenet"},{"issue":"1","key":"3629_CR16","doi-asserted-by":"publisher","first-page":"55","DOI":"10.7754\/clin.lab.2013.121137","volume":"60","author":"CA Abdelmalak","year":"2014","unstructured":"Abdelmalak CA, Yahya RS, Elghannam DM, El-Khadragy AE, Abd-El-Messih HM (2014) PRAME gene expression in childhood acute lymphoblastic leukemia: impact on prognosis. Clin Lab 60(1):55\u201361. https:\/\/doi.org\/10.7754\/clin.lab.2013.121137","journal-title":"Clin Lab"},{"issue":"9","key":"3629_CR17","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1002\/gcc.20465","volume":"46","author":"T Schenk","year":"2007","unstructured":"Schenk T, Stengel S, Goellner S, Steinbach D, Saluz HP (2007) Hypomethylation of PRAME is responsible for its aberrant overexpression in human malignancies. Genes Chromosomes Cancer 46(9):796\u2013804. https:\/\/doi.org\/10.1002\/gcc.20465","journal-title":"Genes Chromosomes Cancer"},{"key":"3629_CR18","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.canlet.2017.06.015","volume":"403","author":"YK Lee","year":"2017","unstructured":"Lee YK, Park UH, Kim EJ, Hwang JT, Jeong JC, Um SJ (2017) Tumor antigen PRAME is up-regulated by MZF1 in cooperation with DNA hypomethylation in melanoma cells. Cancer Lett 403:144\u2013151. https:\/\/doi.org\/10.1016\/j.canlet.2017.06.015","journal-title":"Cancer Lett"},{"issue":"3","key":"3629_CR19","doi-asserted-by":"publisher","first-page":"665","DOI":"10.3892\/ijo.2011.1084","volume":"39","author":"E Sakurai","year":"2011","unstructured":"Sakurai E, Maesawa C, Shibazaki M, Yasuhira S, Oikawa H, Sato M, Tsunoda K, Ishikawa Y, Watanabe A, Takahashi K, Akasaka T, Masuda T (2011) Downregulation of microRNA-211 is involved in expression of preferentially expressed antigen of melanoma in melanoma cells. Int J Oncol 39(3):665\u2013672. https:\/\/doi.org\/10.3892\/ijo.2011.1084","journal-title":"Int J Oncol"},{"issue":"11","key":"3629_CR20","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1097\/PAS.0000000000001134","volume":"42","author":"C Lezcano","year":"2018","unstructured":"Lezcano C, Jungbluth AA, Nehal KS, Hollmann TJ, Busam KJ (2018) PRAME Expression in Melanocytic Tumors. Am J Surg Pathol 42(11):1456\u20131465. https:\/\/doi.org\/10.1097\/PAS.0000000000001134","journal-title":"Am J Surg Pathol"},{"issue":"8","key":"3629_CR21","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1177\/10668969211012085","volume":"29","author":"C Lezcano","year":"2021","unstructured":"Lezcano C, M\u00fcller AM, Frosina D, Hernandez E, Geronimo JA, Busam KJ, Jungbluth AA (2021) Immunohistochemical Detection of Cancer-Testis Antigen PRAME. Int J Surg Pathol 29(8):826\u2013835. https:\/\/doi.org\/10.1177\/10668969211012085","journal-title":"Int J Surg Pathol"},{"issue":"11","key":"3629_CR22","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1097\/PAS.0000000000001944","volume":"46","author":"M Kaczorowski","year":"2022","unstructured":"Kaczorowski M, Ch\u0142opek M, Kruczak A, Ry\u015b J, Lasota J, Miettinen M (2022) PRAME Expression in Cancer. A Systematic Immunohistochemical Study of >5800 Epithelial and Nonepithelial Tumors. Am J Surg Pathol. 46(11):1467\u20131476. https:\/\/doi.org\/10.1097\/PAS.0000000000001944","journal-title":"Am J Surg Pathol."},{"issue":"2","key":"3629_CR23","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s00428-022-03338-z","volume":"481","author":"P Dundr","year":"2022","unstructured":"Dundr P, Bazalov\u00e1 B, B\u00e1rt\u016f M, Bosse T, Drozenov\u00e1 J, Fabian P, Fadare O, Hausnerov\u00e1 J, Jak\u0161a R, Laco J, Lax SF, Mat\u011bj R, McCluggage WG, M\u00e9hes G, Mich\u00e1lkov\u00e1 R, N\u011bmejcov\u00e1 K, Singh N, Stolnicu S, \u0160kapa P, \u0160vajdler M, Stru\u017einsk\u00e1 I (2022) The cytokeratin 17 expression in primary ovarian tumors has diagnostic but not prognostic significance. Virchows Arch 481(2):201\u2013212. https:\/\/doi.org\/10.1007\/s00428-022-03338-z","journal-title":"Virchows Arch"},{"issue":"1","key":"3629_CR24","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/his.14904","volume":"83","author":"M Kunc","year":"2023","unstructured":"Kunc M, \u017bemierowska N, Skowronek F, Biernat W (2023) Diagnostic test accuracy meta-analysis of PRAME in distinguishing primary cutaneous melanomas from benign melanocytic lesions. Histopathology 83(1):3\u201314. https:\/\/doi.org\/10.1111\/his.14904","journal-title":"Histopathology"},{"issue":"7","key":"3629_CR25","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1097\/CJI.0b013e3182280db1","volume":"34","author":"JS Weber","year":"2011","unstructured":"Weber JS, Vogelzang NJ, Ernstoff MS, Goodman OB, Cranmer LD, Marshall JL, Miles S, Rosario D, Diamond DC, Qiu Z, Obrocea M, Bot A (2011) A phase 1 study of a vaccine targeting preferentially expressed antigen in melanoma and prostate-specific membrane antigen in patients with advanced solid tumors. J Immunother 34(7):556\u2013567. https:\/\/doi.org\/10.1097\/CJI.0b013e3182280db1","journal-title":"J Immunother"},{"issue":"4","key":"3629_CR26","doi-asserted-by":"publisher","first-page":"e000068","DOI":"10.1136\/esmoopen-2016-000068","volume":"1","author":"R Gutzmer","year":"2016","unstructured":"Gutzmer R, Rivoltini L, Levchenko E, Testori A, Utikal J, Ascierto PA, Demidov L, Grob JJ, Ridolfi R, Schadendorf D, Queirolo P, Santoro A, Loquai C, Dreno B, Hauschild A, Schultz E, Lesimple TP, Vanhoutte N, Salaun B, Gillet M, Jarnjak S, De Sousa Alves PM, Louahed J, Brichard VG, Lehmann FF (2016) Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study. ESMO Open 1(4):e000068. https:\/\/doi.org\/10.1136\/esmoopen-2016-000068","journal-title":"ESMO Open"},{"issue":"7","key":"3629_CR27","doi-asserted-by":"publisher","first-page":"984","DOI":"10.3390\/cancers11070984","volume":"11","author":"G Al-Khadairi","year":"2019","unstructured":"Al-Khadairi G, Decock J (2019) Cancer Testis Antigens and Immunotherapy: Where Do We Stand in the Targeting of PRAME? Cancers (Basel) 11(7):984. https:\/\/doi.org\/10.3390\/cancers11070984","journal-title":"Cancers (Basel)"},{"issue":"22","key":"3629_CR28","doi-asserted-by":"publisher","first-page":"10376","DOI":"10.1111\/jcmm.16967","volume":"25","author":"A Naik","year":"2021","unstructured":"Naik A, Thomas R, Al-Khadairi G, Bacha R, Hendrickx W, Decock J (2021) Cancer testis antigen PRAME: An anti-cancer target with immunomodulatory potential. J Cell Mol Med 25(22):10376\u201310388. https:\/\/doi.org\/10.1111\/jcmm.16967","journal-title":"J Cell Mol Med"},{"issue":"29","key":"3629_CR29","doi-asserted-by":"publisher","first-page":"45352","DOI":"10.18632\/oncotarget.9977","volume":"7","author":"W Zhang","year":"2016","unstructured":"Zhang W, Barger CJ, Eng KH, Klinkebiel D, Link PA, Omilian A, Bshara W, Odunsi K, Karpf AR (2016) PRAME expression and promoter hypomethylation in epithelial ovarian cancer. Oncotarget 7(29):45352\u201345369. https:\/\/doi.org\/10.18632\/oncotarget.9977","journal-title":"Oncotarget"},{"issue":"2","key":"3629_CR30","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1309\/AJCPGA95KVSAUDMF","volume":"137","author":"K Brenne","year":"2012","unstructured":"Brenne K, Nymoen DA, Reich R, Davidson B (2012) PRAME (preferentially expressed antigen of melanoma) is a novel marker for differentiating serous carcinoma from malignant mesothelioma. Am J Clin Pathol 137(2):240\u2013247. https:\/\/doi.org\/10.1309\/AJCPGA95KVSAUDMF","journal-title":"Am J Clin Pathol"},{"issue":"9","key":"3629_CR31","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1002\/ijc.23758","volume":"123","author":"K Partheen","year":"2008","unstructured":"Partheen K, Levan K, Osterberg L, Claesson I, Fallenius G, Sundfeldt K, Horvath G (2008) Four potential biomarkers as prognostic factors in stage III serous ovarian adenocarcinomas. Int J Cancer 123(9):2130\u20132137. https:\/\/doi.org\/10.1002\/ijc.23758","journal-title":"Int J Cancer"},{"issue":"1","key":"3629_CR32","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1097\/PGP.0000000000000864","volume":"42","author":"JD Coppock","year":"2023","unstructured":"Coppock JD, Gradecki SE, Mills AM (2023) PRAME Expression in Endometrioid and Serous Endometrial Carcinoma: A Potential Immunotherapeutic Target and Possible Diagnostic Pitfall. Int J Gynecol Pathol 42(1):35\u201342. https:\/\/doi.org\/10.1097\/PGP.0000000000000864","journal-title":"Int J Gynecol Pathol"},{"issue":"1","key":"3629_CR33","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13000-023-01317-9","volume":"18","author":"K N\u011bmejcov\u00e1","year":"2023","unstructured":"N\u011bmejcov\u00e1 K, \u0160afanda A, B\u00e1rt\u016f MK, Mich\u00e1lkov\u00e1 R, Drozenov\u00e1 J, Fabian P, Hausnerov\u00e1 J, Laco J, Mat\u011bj R, M\u00e9hes G, \u0160kapa P, Stru\u017einsk\u00e1 I, Dundr P (2023) A comprehensive immunohistochemical analysis of 26 markers in 250 cases of serous ovarian tumors. Diagn Pathol 18(1):32. https:\/\/doi.org\/10.1186\/s13000-023-01317-9","journal-title":"Diagn Pathol"},{"issue":"1","key":"3629_CR34","doi-asserted-by":"publisher","first-page":"100040","DOI":"10.1016\/j.modpat.2022.100040","volume":"36","author":"P Dundr","year":"2023","unstructured":"Dundr P, B\u00e1rt\u016f M, Bosse T, Bui QH, Cibula D, Drozenov\u00e1 J, Fabian P, Fadare O, Hausnerov\u00e1 J, Hojn\u00fd J, H\u00e1jkov\u00e1 N, Jak\u0161a R, Laco J, Lax SF, Mat\u011bj R, M\u00e9hes G, Mich\u00e1lkov\u00e1 R, \u0160afanda A, N\u011bmejcov\u00e1 K, Singh N, Stolnicu S, \u0160vajdler M, Zima T, Stru\u017einsk\u00e1 I, McCluggage WG (2023) Primary Mucinous Tumors of the Ovary: An Interobserver Reproducibility and Detailed Molecular Study Reveals Significant Overlap Between Diagnostic Categories. Mod Pathol 36(1):100040. https:\/\/doi.org\/10.1016\/j.modpat.2022.100040","journal-title":"Mod Pathol"}],"container-title":["Virchows Archiv"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-023-03629-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00428-023-03629-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-023-03629-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T08:05:08Z","timestamp":1698393908000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00428-023-03629-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,23]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["3629"],"URL":"https:\/\/doi.org\/10.1007\/s00428-023-03629-z","relation":{},"ISSN":["0945-6317","1432-2307"],"issn-type":[{"value":"0945-6317","type":"print"},{"value":"1432-2307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,23]]},"assertion":[{"value":"7 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committee of the General University Hospital in Prague in compliance with the Helsinki Declaration (No. 2140\/19 S-IV). The Ethics Committee waived the requirement for informed consent as according to the Czech Law (Act. no. 373\/11, and its amendment Act no. 202\/17), it is not necessary to obtain informed consent in fully anonymized studies.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing financial and\/or non-financial interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}